CD38 PRODUCT COLLABORATION AGREEMENTCd38 Product Collaboration Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
This CD38 PRODUCT COLLABORATION AGREEMENT (the “Agreement”) is entered into on January 22, 2018 (the “Effective Date”) between I-Mab, a company organized and existing under the laws of Cayman Islands and having its registered address at *** (“I-Mab”), and EVEREST MEDICINES LIMITED, a company organized and existing under the laws of Cayman Islands and having its registered address at *** (“Everest”). Everest and I-Mab are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION AGREEMENT between ABL Bio and I-Mab Dated July 26, 2018Collaboration Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations • New York
This Collaboration Agreement (“Agreement”) is made and entered into as of the date first written above (the “Effective Date”) by and between ABL Bio having a business address at ***, Republic of Korea (“ABL Bio”) and I-Mab, having a business address at *** (“I-Mab ”). For purposes of this Agreement, ABL Bio and I-Mab are each referred to individually as a “Party” and together the “Parties.”
SUPPLEMENTAL AGREEMENT TO CD38 PRODUCT COLLABORATION AGREEMENTSupplemental Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
FERRING INTERNATIONAL CENTER SA and I-MAB LICENSE AND SUBLICENSE AGREEMENTLicense Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
THIS LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is effective as of 4th of November 2016 (the “Effective Date”), and is by and between FERRING INTERNATIONAL CENTER SA, a company organised and existing under the laws of Switzerland and having its principal place of business at *** (“Ferring”) and I-MAB, a company organised and existing under the laws of Cayman Islands and having its principal place of business at ***, (“I-MAB”). Each party individually may be referred to herein as a “Party” and collectively both parties may be referred to herein as the “Parties.”
Contract Number: Product Development Agreement of TG103 Project Between I-Mab Biopharma (Shanghai) Co., Ltd. and CSPC Baike (Shangdong) Biopharmaceutical Co., Ltd. December 10th, 2018Product Development Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
This Intellectual Property Licensing and Product Development Agreement (“this Agreement”) is signed by and between the following parties on December 10th, 2018:
Supplement to the Re-organization Framework AgreementSupplement to the Re-Organization Framework Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
This Supplement to the Re-organization Framework Agreement (hereinafter referred to as this “Supplementary Agreement”) is signed on May 31, 2018 in Tianjin by and among:
GENEXINE, INC. AND TASGEN BIO-TECH (TIANJIN) CO., LTD. INTELLECTUAL PROPERTY ASSIGNMENT AND LICENSE AGREEMENT DATED October 16th, 2015Intellectual Property Assignment and License Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED COLLABORATION AGREEMENTCollaboration Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
GENEXINE, INC. AND I-MAB INTELLECTUAL PROPERTY LICENSE AGREEMENT DATED DECEMBER 22, 2017Intellectual Property License Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations
Genexine and I-Mab have agreed to establish a cooperation relationship with each other, under which Genexine, as the sole and exclusive owner of all the patents, patent applications, know-hows, data and information (the “Licensed Intellectual Properties”), which relate to the Licensed Product (as defined below) and are limited to those listed on Exhibit A attached hereto and may be updated from time to time during the term of this Agreement upon mutual consents of the Parties, intends to grant the License (as defined below) of the Licensed Intellectual Properties to I-Mab so that I-Mab can engage in pre-clinical/clinical development, manufacturing, sale and distribution of the Licensed Product in the Territory (as defined below). I-Mab intends to accept the License of the Licensed Intellectual Properties from Genexine in accordance with this Agreement.
SERIES C SHARE PURCHASE AGREEMENT June 28, 2018Share Purchase Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations • New York
This License and Collaboration Agreement (“Agreement”) is made and entered into effective as of November 30, 2017 (the “Effective Date”), by and between
SERIES C-1 SHARE PURCHASE AGREEMENT July 25, 2019Share Purchase Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
